Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ironwood Pharmaceuticals (IRWD) EBT Margin (2016 - 2025)

Historic EBT Margin for Ironwood Pharmaceuticals (IRWD) over the last 17 years, with Q3 2025 value amounting to 55.73%.

  • Ironwood Pharmaceuticals' EBT Margin rose 367600.0% to 55.73% in Q3 2025 from the same period last year, while for Sep 2025 it was 57.66%, marking a year-over-year increase of 986100.0%. This contributed to the annual value of 47.55% for FY2024, which is 3128500.0% up from last year.
  • Latest data reveals that Ironwood Pharmaceuticals reported EBT Margin of 55.73% as of Q3 2025, which was up 367600.0% from 44.37% recorded in Q2 2025.
  • In the past 5 years, Ironwood Pharmaceuticals' EBT Margin ranged from a high of 139.03% in Q4 2024 and a low of 1002.24% during Q2 2023
  • Moreover, its 5-year median value for EBT Margin was 45.43% (2021), whereas its average is 23.24%.
  • In the last 5 years, Ironwood Pharmaceuticals' EBT Margin tumbled by -10575500bps in 2023 and then skyrocketed by 10222300bps in 2024.
  • Quarter analysis of 5 years shows Ironwood Pharmaceuticals' EBT Margin stood at 39.49% in 2021, then soared by 71bps to 67.41% in 2022, then tumbled by -348bps to 166.88% in 2023, then skyrocketed by 183bps to 139.03% in 2024, then plummeted by -60bps to 55.73% in 2025.
  • Its last three reported values are 55.73% in Q3 2025, 44.37% for Q2 2025, and 88.16% during Q1 2025.